Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at iRhythm (NASDAQ:IRTC) and its peers. Patient monitoring companies within ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Diabetes Care Devices Market Insights, Competitive Landscape, and Market Forecast - 2034” report provides the current ...

Opportunities include integrating digital health for remote care, leveraging demographic trends, and overcoming CGM unit costs to expand access across regionsDublin, March 16, 2026 (GLOBE NEWSWIRE) -- ...

DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

Shares of DexCom Inc. DXCM slipped 3.66% to $68.10 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.33% to 6,740.02 and Dow ...

In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...

The S&P 500 closed barely higher on ⁠Friday, ⁠supported by cooling inflation data, but the Nasdaq ⁠ended lower as heavyweight ...